Search

Your search keyword '"Sakai-Tagawa, Yuko"' showing total 3 results
Start Over Author "Sakai-Tagawa, Yuko" Topic viral antibodies Language english Publisher new england journal of medicine
3 results on '"Sakai-Tagawa, Yuko"'

1. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6.

Author

Emi Takashita, Seiya Yamayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Halfmann, Peter, Wilson, Nancy, Ries, Hunter, Richardson, Alex, Bobholz, Max, Vuyk, William, Maddox, Robert, Baker, David A, Friedrich, Thomas C, O'Connor, David H, Uraki, Ryuta, Ito, Mutsumi, Sakai-Tagawa, Yuko, Adachi, Eisuke, and Saito, Makoto

Subjects
*ANTIVIRAL agents, *VIRAL antibodies, *PHARMACODYNAMICS
Abstract

The article informs about the BA.S subvariant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant has become dominant in most countries around the world. Topics incluyde the amino acid substitutions in the receptorbinding domain of the spike protein, which is the major target for vaccines and therapeutic monoclonal antibodies against SARS-CoV-2; and effectiveness of current vaccines and therapeutic monoclonal antibodies against this subvariant will be decreased.

Published
2022
Full Text
View/download PDF

2. Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.

Author

Emi Takashita, Selya Yarnayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Fukushi, Shuetsu, Suzuki, Tadaki, Maeda, Ken, Sakai-Tagawa, Yuko, Ito, Mutsumi, Uraki, Ryuta, Halfmann, Peter, Watanabe, Shinji, Takeda, Makoto, Hasegawa, Hideki, Imai, Masaki, and Kawaoka, Yoshihiro

Subjects
*IMMUNOGLOBULINS, *ANTIVIRAL agents, *RESEARCH funding, *VIRAL antibodies
Published
2022
Full Text
View/download PDF

3. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.

Author

Emi Takashita, Seiya Yarnayoshi, Yoshihiro Kawaoka, Takashita, Emi, Yamayoshi, Seiya, Simon, Viviana, van Bakel, Harm, Sordillo, Emilia M, Pekosz, Andrew, Fukushi, Shuetsu, Suzuki, Tadaki, Maeda, Ken, Halfmann, Peter, Sakai-Tagawa, Yuko, Ito, Mutsumi, Watanabe, Shinji, Imai, Masaki, Hasegawa, Hideki, and Kawaoka, Yoshihiro

Subjects
*IMMUNOGLOBULINS, *MONOCLONAL antibodies, *ANTIVIRAL agents, *VIRAL antibodies
Abstract

The article discusses The data from our trial suggest that dulaglutide , if ultimately approved for pediatric use, may offer advantages not only with regard to glycemic control but also with regard to its frequency and method of administration. Weekly administration with a device that does not require reconstitution steps or needle handling and that has shown favorable ease-of-use characteristics in preference studies involving.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results